Загрузка...
Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable ther...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6529614/ https://ncbi.nlm.nih.gov/pubmed/31190866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S198946 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|